A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Key claim: This early-phase trial is evaluating the safety, tolerability, maximum tolerated dose, and recommended expansion dose of INCA033989 alone or combined with ruxolitinib in MPN patients.
Abstract
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Why this matters
INCA033989 represents another novel investigational agent entering the ruxolitinib add-on combination portfolio for MPNs, joining a growing list (selinexor, pelabresib, roginolisib, INCB057643, tasquinimod) where ruxolitinib serves as the standard JAK-inhibitor backbone. As a first-in-human Phase 1 study with undisclosed mechanism, the trial currently informs only the development pipeline landscape; efficacy and mechanistic relevance remain to be established.